摘要
目的 评价重组组织型纤溶酶原激活剂 (rt PA)在院前救治急性心肌梗死 (AMI)的近期临床治疗效果 ,并探讨在院前对AMI患者进行静脉溶栓治疗的安全性和可行性。方法 对所收治的AMI患者进行分组 ,均给予rt PA( 5 0mg)进行静脉溶栓治疗 ,对比两者的冠状动脉再通率以及发病至溶栓时间延迟对rt PA静脉溶栓疗效的影响。结果 从患者发病至进行溶栓治疗的时间间隔 ,院前组平均比院内组缩短 2 .2小时 [( 2 .9± 1.4)小时比 ( 5 .1± 1.1)小时 ] ,P <0 .0 5 ;院前治疗组的冠状动脉总再通率为 90 % ,明显高于院内治疗组的 61.8% (P <0 .0 5 )。结论 院前应用rt PA( 5 0mg)进行静脉溶栓治疗安全、可行。
Objective To determine the therapeutic effect of prehospital intravenous thrombolytic therapy in patients with acute myocardial infarction(AMI),and to verify the safety and practicability of intravenous thrombolytic therapy.Methods Among enrolled AMI patients,seventy ones receiving rt-PA(50mg) were included in the study as prehospital group,and sisty eight ones received the same therapy in hospital was included as the inhospital group.Results The interval from symptom onset to thrombolytic therapy in prehospital group was 2.2 hours shorter than that in inhospital group(2.9h±1.4 h vs 5.1h± 1.1h, P<0.05).The total reopening rate of coronary blood vessel was 90% in prehospital group,and 61.8% in inhospital group(P<0.05).Conclusion Prehospital intravenous thrombolytic therapy with rt-PA in AMI patients is safe and practical.
出处
《临床内科杂志》
CAS
北大核心
2004年第6期390-392,共3页
Journal of Clinical Internal Medicine
